News

Two-thirds of high severity likely due to upcoding, according to a RAND study of hospitalizations in five states.

PEPFAR, the main U.S.-funded global AIDS program was given a waiver from the foreign aid freeze, but there is still uncertainty and interruptions, partly because many PEPFAR programs are implemented through USAID, which has been largely shutdown by the news administration.

Medically tailored meals are an appealing idea, but there is little regulation or standardization.

Lindsay Bealor Greenleaf, head of Federal and State Policy at ADVI Health, talks with Managed Healthcare Executive about Robert F. Kennedy Jr., President Donald Trump’s HHS secretary nominee.

Laurie Ratliff was diagnosed with metastatic breast cancer 25 years ago, and she’s continuing to beat the odds while advocating for aesthetic flat closure as a viable breast reconstruction option.

The technology to leverage healthcare data exists. The problem, according to Highlander Health, is outdated structures and silos.

The quality-adjusted life years has shown staying power in cost-effectiveness calculations, but some say it has major flaws and have proposed alternatives.

An overview of menopause taboo, the lingering effects of the Women’s Health Initiative study and what employers can do support their menopausal workers, according to Stephanie Faubion, M.D., director of the Mayo Clinic’s Center for Women’s Health and medical director of The Menopause Society.

The Senate Finance Committee voted 14-13 along party lines this morning to send the nomination of Robert F. Kennedy Jr. to be HHS Secretary to the full Senate.

This follows the company’s recent earnings call, where executives discussed the organization’s growth and future plans, highlighting its focus on serving the best interests of their consumers.

Potential threats to HIV care and fallout over the next four years, according to Jose Abrigo, Esq., HIV project director at Lambda Legal Defense and Education Fund and Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.

Much of the association between trauma and suicide risk among university students can be explained by shame, a new study finds.

Here’s what you missed this week on Managed Healthcare Executive.

A new bipartisan bill aims to cancel the 2.83% cut to Medicare payments to physician practices.

As a non-opioid drug, Journavx can assist patients effectively and without showing signs of being addictive.

The Cigna Group reported today their total revenue of $247.1 billion for 2024, compared with $195.3 billion in 2023. This growth highlights the company’s strong financial results, supported by the success of Evernorth Health Services, new client acquisitions and growth in the specialty drug space.

After several days of worry that the global AIDS program might come to abrupt end, Secretary of State Marco Rubio issued a humanitarian waiver that appears to have restored funding.

At today's confirmation hearing, Democratic senators were skeptical of the HHS Secretary nominee Robert F. Kennedy Jr.'s claim that he is now pro-vaccine.

Robert F. Kennedy Jr., the HHS secretary nominee, has said he is not antivaccine, but he has a track record of casting doubt on the safety and efficacy of vaccines.

In 2021 book attacking Anthony Fauci, M.D., Robert F. Kennedy Jr. casts doubt on HIV being the sole cause of AIDS and presents arguments made by "HIV deniers" that believe it is bystander in the immunosuppression that characterizes AIDS.

The survey also showed that high drug costs and artificial intelligence are topmost among the respondent’s concerns.

In this new role, Flaster will lead Cigna Healthcare’s clinical organization, focusing on initiatives to improve customer experience and deliver better health outcomes

As the nation is again under the reigns of a Trump administration and a Republican-led Congress, debates on reducing spending have not affected the public’s feelings on these programs.

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research shows.

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one prior treatment. The FDA simultaneously converted the conditional approval to full approval for this indication.

Here’s what you missed this week on Managed Healthcare Executive.

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.